Memorial Sloan Kettering Cancer Center

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Myeloma
Leukemia
Lymphoma
Hematologic Transplantation and Malignancies
Breast
Lung
Gastrointestinal
Genitourinary
Gynecologic
Skin
Head and Neck
Brain
General Oncology
Palliative Care
MPN
COVID-19
Events

Playback speed

10 seconds

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MBC With Low HER2 Expression

By ecancer FEATURING Shanu Modi

37 views

June 17, 2022

Comments 0

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Breast

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

578 views

ESMO 2023 Insights: "EMBER Study - Imlunestrant+/-Everolimus or Alpe…

Insights from 2023 ESMO Annual Meeting

K. Jhaveri

152 views

Early Diagnosis and Updates in Breast Cancer

Memorial Sloan Kettering Cancer Center

V. Sacchini

166 views

ASCO 2022 HR+ Breast Cancer Updates

Nebraska Oncology Society

C. Dang

595 views

ASCO 2022 on the Phase 3 DESTINY-Breast 03 Trial: HER2+ BC Updates

Nebraska Oncology Society

C. Dang

49 views

ASCO 2022 on the Phase 3 KEYNOTE-522 Trial: TNBC Updates

Nebraska Oncology Society

C. Dang

72 views

ASCO 2022 Preliminary Analysis of an Expanded Access Study of the Fi…

ASCO 2022 Conference Coverage

C. Dang

198 views

Lecture Summary - ASCO 2022 Preliminary Analysis of an Expanded Acce…

ASCO 2022 Conference Coverage

C. Dang

40 views

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MB…

ecancer

S. Modi

37 views

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan vs. Treatment of …

ecancer

S. Modi

218 views

ASCO 2022 on Characterization of Alpelisib-Associated Hyperglycemia …

ASCO 2022 Conference Coverage

S. Shen

364 views

Lecture Summary - ASCO 2022 on Characterization of Alpelisib-Associa…

ASCO 2022 Conference Coverage

S. Shen

18 views

HER2- Directed Targeted Agents for Brain Metastasis in Metastatic Br…

Memorial Sloan Kettering Cancer Center

N. Iyengar

662 views

2022 Inherited Breast Cancer Risk Assessment and Reduction: What's N…

University of Kansas Cancer Center Post San Antonio Review

M. Robson

44 views

HR+ Breast Cancer: Individualizing Therapy With CDK 4/6 Inhibitors

PleXus Communications

K. Jhaveri

338 views

SABCS 2021 Results of a Prospective Screening Study: Impact of Race …

SABCS 2021 Conference Coverage on VuMedi

A. Barrio

13 views

SABCS 2021 Updates on Neratinib + Fulvestrant + Trastuzumab for HR+/…

SABCS 2021 Conference Coverage on VuMedi

K. Jhaveri

277 views

SABCS 2021 Update on Oligoprogressive Disease in BC: Treating Locall…

SABCS 2021 Conference Coverage on VuMedi

A. Xu

505 views

Will Surgery Be a Part of Breast Cancer Treatment in the Future?

Memorial Sloan Kettering Cancer Center

M. Morrow

3.8K views

CAR-T Cell Therapy for Breast Cancer: Types of T-Cell Therapy, Ident…

5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

S. Modi

826 views